Predictive value of baseline serum HBV RNA levels for HBeAg seroconversion in chronic hepatitis B patients with advanced fibrosis/compensated cirrhosis undergoing tenofovir disoproxil fumarate treatment
10.3760/cma.j.cn114452-20240816-00460
- VernacularTitle:基线血清HBV RNA水平对TDF治疗CHB合并进展期肝纤维化/代偿期肝硬化患者HBeAg血清学转换的预测价值
- Author:
Haiying ZHANG
1
;
Zhenyu WANG
;
Yuyuan JIA
;
Hongsong CHEN
;
Huiying RAO
Author Information
1. 北京大学人民医院 北京大学肝病研究所 丙型肝炎和肝病免疫治疗北京市重点实验室 非酒精性脂肪性肝病诊断北京市国际科技合作基地，北京 100044
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis B;
Hepatic fibrosis;
Compensated liver cirrhosis;
Nucleoside analogue;
Hepatitis B virus pregenomic RNA;
Hepatitis B e antigen;
Seroconver
- From:
Chinese Journal of Laboratory Medicine
2025;48(1):49-55
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the predictive value of baseline serum levels of hepatitis B virus (HBV) RNA for HBeAg seroconversion in chronic hepatitis B (CHB) subjects with advanced fibrosis/compensated cirrhosis undergoing tenofovir disoproxil fumarate (TDF) therapy.Methods:A case-control study was conducted on 141 patients with CHB combined with advanced fibrosis/compensated cirrhosis who were treated with TDF and tested at Peking University People′s Hospital from January 2015 to December 2020. Patients were divided into HBeAg seroconversion (16 cases) group and non-seroconversion (59 cases) group based on whether HBeAg seroconversion occurred at 240 weeks after treatment. The patients were divided into HBeAg positive and negative groups at baseline (75 and 66 cases, repectively) and at 12 weeks treatment (61 and 80 cases, repectively). The baseline serum levels of relevant indicators were analyzed. HBV RNA levels were measured at baseline and at 240 weeks after treatment. The correlation between HBV RNA and HBV DNA was analyzed using Pearson correlation analysis, and the predictive value was evaluated using the receiver operating characteristic (ROC) curve.Results:For the 75 HBeAg-positive patients at baseline, 21.3% (16/75) achieved HBeAg seroconversion. The HBV DNA and HBV RNA in the HBeAg-positive group were significantly higher than that in the HBeAg-negative group (all P<0.001). Compared with the non-seroconversion group, the HBeAg seroconversion group had significantly lower baseline serum levels of HBV RNA ( P<0.05). Pearson correlation analysis showed that serum HBV RNA levels were positively correlated with HBV DNA in both baseline and 12 weeks HBeAg-negative group and HBeAg-positive group, respectively (baseline: r=0.718, 0.794, P<0.001; 12 weeks: r=0.689, 0.750, P<0.001). ROC curve showed that baseline levels of HBV RNA could be used as a predictor of HBeAg seroconversion in CHB patients with advanced fibrosis/compensated cirrhosis treated with TDF. The area under curve was 0.781, the sensitivity was 75.0%, and the specificity was 78.0%. Conclusion:Baseline serum levels of HBV RNA has a predictive value for HBeAg seroconversion in CHB patients with advanced fibrosis/compensated cirrhosis treated with TDF.
